Phase 3 Recruiting Network
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in diff…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT03937635
Sites in New York: - Glens Falls Hospital — Glens Falls, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
- Upstate Cancer Center at Oswego — Oswego, New York
- State University of New York Upstate Medical University — Syracuse, New York
- SUNY Upstate Medical Center-Community Campus — Syracuse, New York
Phase 3 Recruiting Network
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of c…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04566328
Sites in New York: - Hematology Oncology Associates of Central New York-Auburn — Auburn, New York
- Lourdes Hospital — Binghamton, New York
- Hematology Oncology Associates of Central New York-East Syracuse — East Syracuse, New York
- Glens Falls Hospital — Glens Falls, New York
- University of Rochester — Rochester, New York
Phase 3 Recruiting Network
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are consid…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05561387
Sites in New York: - NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center — New York, New York
- University of Rochester — Rochester, New York
Phase 3 Recruiting Industry
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years …
Sponsor: Pfizer
NCT ID: NCT06152575
Sites in New York: - WMCHealth Advanced Physician Services — Hawthorne, New York
- Northwell Health/ RJ Zuckerberg Cancer Center — Lake Success, New York
- North Shore University Hospital — Manhasset, New York
- Long Island Jewish Medical Center — New Hyde Park, New York
- Westchester Medical Center — Valhalla, New York
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexam…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05552222
Sites in New York: - Hematology-Oncology Associates of CNY — East Syracuse, New York
- Northwell Health Cancer Institute — Lake Success, New York
- NYU Langone Hospital Long Island — Mineola, New York
- Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple m…
Sponsor: Celgene
NCT ID: NCT05519085
Sites in New York: - Local Institution - 0245 — Buffalo, New York
- Northwell Health/ RJ Zuckerberg Cancer Center — Lake Success, New York
- Local Institution - 0373 — New Hyde Park, New York
- Local Institution - 0371 — New York, New York
- Rochester General Hospital — Rochester, New York
Phase 3 Recruiting Industry
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, inclu…
Sponsor: Kite, A Gilead Company
NCT ID: NCT06413498
Sites in New York: - Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Weill Cornell Medicine - New York Presbyterian Hosptial — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dex…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06208150
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Weill Cornell Medical College — New York, New York
- SUNY Upstate Medical University — Syracuse, New York
Phase 3 Recruiting Industry
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…
Sponsor: AbbVie
NCT ID: NCT06158841
Sites in New York: - New York Cancer & Blood Specialists - Bay Shore /ID# 261524 — Bay Shore, New York
- New York Cancer & Blood Specialists - Lake Success Medical Oncology /ID# 262953 — New Hyde Park, New York
- New York Cancer and Blood Specialists - New York /ID# 262951 — New York, New York
- Eastchester Center for Cancer Care /ID# 262952 — The Bronx, New York
Phase 3 Recruiting Industry
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Sponsor: Bristol-Myers Squibb
NCT ID: NCT05827016
Sites in New York: - Local Institution - 0328 — Brooklyn, New York
- Perlmutter Cancer Center at NYU Langone Hematology Oncology Associates-Mineola — Mineola, New York
- NYU Langone Health — New York, New York
- Columbia University Medical Center - Herbert Irving Pavilion Location — New York, New York
- Clinical Research Alliance — Westbury, New York
Phase 3 Recruiting Industry
This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, …
Sponsor: AstraZeneca
NCT ID: NCT07391657
Sites in New York: - Research Site — New York, New York
- Research Site — New York, New York
- Research Site — New York, New York
- Research Site — Rochester, New York
- Research Site — The Bronx, New York
Phase 3 Recruiting Network
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as …
Sponsor: European Myeloma Network B.V.
NCT ID: NCT05243797
Sites in New York: - Mount Sinai Medical Center - 2 — New York, New York
- Montefiore Medical Cente — The Bronx, New York
Phase 3 Recruiting Industry
The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dex…
Sponsor: Pfizer
NCT ID: NCT05020236
Sites in New York: - MSK Commack — Commack, New York
- MSK Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). — New York, New York
- Memorial Sloan Kettering Cancer Center - Main Campus — New York, New York
- MSK Nassau — Uniondale, New York
Phase 3 Recruiting Industry
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
Sponsor: GlaxoSmithKline
NCT ID: NCT06679101
Sites in New York: - GSK Investigational Site — Stony Brook, New York
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06615479
Sites in New York: - Local Institution - 0229 — New York, New York
- Local Institution - 0221 — Stony Brook, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07258511
Sites in New York: - Mount Sinai Brooklyn — Brooklyn, New York
- Mount Sinai Chelsea — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2, Phase 3 Recruiting Industry
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney fail…
Sponsor: AbbVie
NCT ID: NCT07095452
Sites in New York: - Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946 — New York, New York
Phase 3 Recruiting Industry
This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05730036
Sites in New York: - Stony Brook University — Stony Brook, New York
Phase 3 Recruiting Industry
Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multip…
Sponsor: Takeda
NCT ID: NCT06980480
Sites in New York: - New York Oncology Hematology — Albany, New York
Phase 3 Recruiting Industry
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05438043
Sites in New York: - Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 3 Recruiting Industry
This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive Multiple Myelo…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT07222761
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Academic/Other
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in New York: - Northwell Health Monter Cancer Center — Lake Success, New York
- Northern Westchester Hospital — Mount Kisco, New York
- Cohen Children's Medical Center — New Hyde Park, New York
- Manhattan Eye, Ear, and Throat Hospital — New York, New York
- Staten Island University Hospital — New York, New York
Phase 2 Recruiting NIH
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myelo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06179888
Sites in New York: - Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NCT ID: NCT06297226
Sites in New York: - Roswell Park Cancer Institute — Buffalo, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
Phase 1, Phase 2 Recruiting Academic/Other
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after a period o…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06232044
Sites in New York: - Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York